Status:
COMPLETED
Topical Heparin for Prevention of Hypertrophic Scarring in Split-Thickness Skin Graft Donor Sites
Lead Sponsor:
Dr. Ruth K.M. Pfau Civil Hospital, Karachi
Conditions:
Hypertrophic Scarring
Pain, Postoperative
Eligibility:
All Genders
2+ years
Phase:
NA
Brief Summary
This study is testing whether applying a special dressing soaked with heparin (a medicine that improves blood flow and reduces scar formation) can help prevent thick, raised scars (called hypertrophic...
Detailed Description
Hypertrophic scarring at the donor site of split-thickness skin grafts (STSG) is a common problem that can cause pain, itching, discomfort, and cosmetic concerns. Conventional donor site dressings all...
Eligibility Criteria
Inclusion
- Patients of age 2 years and above, of any gender.
- Patients requiring a split-thickness skin graft.
- Patients giving informed consent for study participation.
- Patients with serum albumin \> 3 g/dL.
Exclusion
- Patients allergic to heparin.
- Patients with diabetes, hematological disorders, kidney or liver diseases, or malignancies.
- Patients on medications affecting wound healing.
- Patients with existing hypertrophic scarring at the donor site
Key Trial Info
Start Date :
August 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07196358
Start Date
August 15 2024
End Date
September 10 2025
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Plastic & Reconstructive Surgery Department, Ruth Pfau Civil Hospita
Karachi, Sindh, Pakistan